Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
about
Antagonistic analogs of growth hormone-releasing hormone increase the efficacy of treatment of triple negative breast cancer in nude mice with doxorubicin; A preclinical studyPotentiating effects of GHRH analogs on the response to chemotherapy.Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinasesNovel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer.Beneficial effects of novel antagonists of GHRH in different models of Alzheimer's diseaseNew therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones.Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1-STAT3/NF-κB signalingNew agonist- and antagonist-based treatment approaches for advanced prostate cancer.Agonists of luteinizing hormone-releasing hormone in prostate cancer.Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells.Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer.Antagonists of growth hormone-releasing hormone inhibit proliferation induced by inflammation in prostatic epithelial cells.
P2860
Q34781112-59CA3AF0-79AE-45D1-AE06-B489A67A82CCQ35565027-EE9E8362-3770-4CBF-B5A7-08330C17FC61Q35749794-CD4ECBA4-4622-449B-926B-F9528244A7DAQ36189529-A84474F5-AD0B-4313-9889-159F18C3C6C3Q36472257-64156C6D-BC93-4264-A437-BED539AD3222Q36576387-1C886B53-19DE-4F2A-A8F9-4ED4E350423AQ36748502-F2BB34CE-2F0B-4FA8-9321-945536FA2CC5Q37519616-1723489B-44C5-4946-99F6-FEBA58937578Q37534187-5EA5DF26-5A30-4320-A525-A1F768FF36C8Q38042768-88794F62-B1E3-4847-B5B4-B2DF3BA96A3BQ38132229-07B28A88-20A5-4332-BCF5-6B0019689914Q39220493-AEBBEFC5-21D5-416B-B55A-46B8C107EA54Q39317388-47402DBD-D39A-4694-A603-92619B77233CQ40018470-4722620E-9A6D-4F32-9243-E94AE044A777Q42321749-7B6DED29-BE94-453C-9366-D35302E614C8
P2860
Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Inhibitory effects of antagoni ...... n p21 and mutant p53 proteins.
@en
Inhibitory effects of antagoni ...... n p21 and mutant p53 proteins.
@nl
type
label
Inhibitory effects of antagoni ...... n p21 and mutant p53 proteins.
@en
Inhibitory effects of antagoni ...... n p21 and mutant p53 proteins.
@nl
prefLabel
Inhibitory effects of antagoni ...... n p21 and mutant p53 proteins.
@en
Inhibitory effects of antagoni ...... n p21 and mutant p53 proteins.
@nl
P2093
P2860
P50
P356
P1433
P1476
Inhibitory effects of antagoni ...... in p21 and mutant p53 proteins
@en
P2093
Anton Stangelberger
Benjamin Baker
Jozsef L Varga
Marta Zarandi
P2860
P304
P356
10.1002/PROS.21458
P577
2011-07-27T00:00:00Z